{
    "clinical_study": {
        "@rank": "11563", 
        "arm_group": [
            {
                "arm_group_label": "Misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "400\u00b5g oral misoprostol"
            }, 
            {
                "arm_group_label": "Oxytocin", 
                "arm_group_type": "Active Comparator", 
                "description": "20 IU oxytocin"
            }
        ], 
        "brief_summary": {
            "textblock": "Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women.\n      Oxytocin is widely used for prevention of PPH. Some studies suggested misoprostol as an\n      alternative treatment when Oxytocin isn't available. The aim of this study is to compare the\n      safety and efficacy of Oxytocin and misoprostol for prevention of PPH."
        }, 
        "brief_title": "Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Partum Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "In a double blind randomized controlled trial 400 pregnant women who has vaginal delivery at\n      Shariati hospital are assigned into two groups either to receive 20 unite oxytocin in 1000cc\n      ringer and 2 placebo tablet or 400mcg oral misoprostol and 2cc normal saline in 1000cc\n      ringer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  were women with singleton pregnancy\n\n          -  with cephalic presentation\n\n          -  who had NVD spontaneously or by induction\n\n        Exclusion Criteria:\n\n          -  placenta previa\n\n          -  placental detachment\n\n          -  coagulation problems\n\n          -  previous CS\n\n          -  macrosomia\n\n          -  Polyhydramnios\n\n          -  and uncontrolled asthma"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863706", 
            "org_study_id": "Misoprostol for PPH"
        }, 
        "intervention": [
            {
                "arm_group_label": "Misoprostol", 
                "description": "400\u00b5g oral misoprostol", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug", 
                "other_name": "Cytotec"
            }, 
            {
                "arm_group_label": "Oxytocin", 
                "description": "20 IU Oxytocin", 
                "intervention_name": "Oxytocin", 
                "intervention_type": "Drug", 
                "other_name": "Syntocinon"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxytocin", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Misoprostol", 
            "Oxytocin", 
            "Post Partum Hemorrhage (PPH)", 
            "Third stage of labour"
        ], 
        "lastchanged_date": "May 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bandar Abbas", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Hormozgan", 
                    "zip": "097145-3388"
                }, 
                "name": "Hormozgan University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage", 
        "other_outcome": {
            "description": "Diarrhea, Vommiting, Fever, Chills", 
            "measure": "Side effects", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "overall_official": [
            {
                "affiliation": "Hormozgan University of Medical Sciences", 
                "last_name": "Minoo Rajaei, Dr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hormozgan University of Medical Sciences", 
                "last_name": "Zohreh Shahboodaghi, Dr", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "within 1 hours after delivery", 
            "measure": "Amount of bleeding", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863706"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hormozgan University of Medical Sciences", 
            "investigator_full_name": "Hamidreza Mahboobi", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hemoglobin decrease", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Hematocrite decrease", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Hormozgan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hormozgan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}